San Diego-dependent Viking Therapeutics marked alone as a serious competitor during the weight loss drug industry in February immediately after revealing promising information from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in M